A Phase 1 interventional study of KPCXM18 and Placebo in Healthy, sponsored by Kunming Pharmaceuticals, Inc.. Status unknown. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-19.
Sponsored by Kunming Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
to assess the safety,Tolerability, and pharmacokinetic of KPCXM18 for injection in healthy subjects
To explore the safety, tolerance and pharmacokinetic of KPCXM18 for injection in healthy subjects by intravenous administration of different doses in single and multiple administration safety, tolerance and pharmacokinetic tests, and to obtain the safe dose range of the test drugs, thus providing dose design basis for phase II clinical trials.
8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.
This study's planned enrollment of 102 is above the median of 48 across 6,037 interventional studies indexed under Stroke.
Browse Stroke studies →Kunming Pharmaceuticals, Inc. is the lead sponsor of 9 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
KPCXM18 ,freeze-dried powder,single and multiple ascending doses, Intravenous route
Drug: KPCXM18 · Drug: Placebo
Placebo, freeze-dried powder,single and multiple ascending doses, Intravenous route
Drug: KPCXM18 · Drug: Placebo
KPCXM18,blind,freeze-dried powder,ascending doses,Intravenous route
Placebo,blind,freeze-dried powder,ascending doses,Intravenous route
Number of subjects with abnormal vital signs
To evaluate the safety KPCXM 18 for Injection with placebo after multiple intravenous dose in healthy Chinese subjects in terms of abnormal vital signs
Time frame: through study completion, an average of 2 week
Number of subjects with abnormal laboratory
To evaluate the safety KPCXM 18 for Injection with placebo after multiple intravenous dose in healthy Chinese subjects in terms of abnormal laboratory
Time frame: through study completion, an average of 2 week
Number of subjects with abnormal physical examination
To evaluate the safety KPCXM 18 for Injection with placebo after multiple intravenous dose in healthy Chinese subjects in terms of abnormal physical examination
Time frame: through study completion, an average of 2 week
Number of subjects with abnormal electrocardiogram
To evaluate the safety KPCXM 18 for Injection with placebo after multiple intravenous dose in healthy Chinese subjects in terms of abnormal electrocardiogram
Time frame: through study completion, an average of 2 week
Number of subjects with adverse events
To evaluate the safety KPCXM 18 for Injection with placebo after multiple intravenous dose in healthy Chinese subjects in terms of abnormal adverse events
Time frame: through study completion, an average of 2 week
Pharmacokinetics of KPCXM18 in plasma: Cmax
To characterize the pharmacokinetic parameters:Cmax of KPCXM18 after the first day administer
Time frame: Time Frame: Between Day 1 to 7 days
Pharmacokinetics of KPCXM18 in plasma: Tmax
To characterize the pharmacokinetic parameters:Tmax of KPCXM18 after the first day administer
Time frame: Time Frame: Between Day 1 to 7 days
Pharmacokinetics of KPCXM18 in plasma: AUC0-∞
To characterize the pharmacokinetic parameters: AUC0-∞ of KPCXM18 after the first day administer
Time frame: Time Frame: Between Day 1 to 7 days
Pharmacokinetics of KPCXM18 in plasma:t1/2
To characterize the pharmacokinetic parameters: t1/2 of KPCXM18 after the
Time frame: Time Frame: Between Day 1 to 7 days
Pharmacokinetics of KPCXM18 in plasma: Cmax,ss
To characterize the pharmacokinetic parameters:Cmax,ss of KPCXM18 after the 14th day administer
Time frame: Time Frame: Between Day 1 to 14 days
Pharmacokinetics of KPCXM18 in plasma: AUC0-∞,ss
To characterize the pharmacokinetic parameters:AUC0-∞,ss of KPCXM18 after the 14th day administer
Time frame: Time Frame: Between Day 1 to 14 days
Pharmacokinetics of KPCXM18 in plasma: Tmax,ss
To characterize the pharmacokinetic parameters:Tmax,ss of KPCXM18 after the 14th day administer
Time frame: Time Frame: Between Day 1 to 14 days
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2020; primary completion for Dec 2021, 13 months later.
Of 26 industry-sponsored phase 1 interventional studies under Stroke, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's planned 13 months is above that.
Counting every sponsor, half of 97 studies reached it within 20 months; a quarter within 7 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kunming Pharmaceuticals, Inc.